Omeros beats Q4 earnings estimates, shares rise 5%

Published 31/03/2025, 22:18
Omeros beats Q4 earnings estimates, shares rise 5%

SEATTLE - Omeros Corporation (NASDAQ:OMER) reported better-than-expected fourth quarter earnings on Monday, sending its shares up 5% in after-hours trading.

The biopharmaceutical company posted a net loss of $31.4 million, or $0.54 per share, for Q4 2024, beating analyst estimates of a $0.69 per share loss. This compares to a net loss of $32.2 million, or $0.56 per share, in Q3 2024.

Omeros did not report any revenue for the quarter. However, the company earned $10.1 million in royalties from Rayner’s U.S. sales of OMIDRIA, up from $9.3 million in Q3.

"We are pleased to announce that our narsoplimab BLA for the treatment of TA-TMA was resubmitted to FDA earlier this month, with the MAA slated for European submission in the coming quarter," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros.

The company expects FDA action on the narsoplimab biologics license application in September 2025. Omeros is also advancing clinical trials for its MASP-3 inhibitor zaltenibart in paroxysmal nocturnal hemoglobinuria.

For the full year 2024, Omeros reported a net loss of $156.8 million, or $2.70 per share, compared to a net loss of $117.8 million, or $1.88 per share, in 2023.

The company ended the year with $90.1 million in cash and short-term investments, down from $171.8 million at the end of 2023. Omeros attributed the decrease partly to $42.7 million in significant cost outlays during 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.